Literature DB >> 10853194

[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis].

J Martínez Ara1, R Gómez Rioja, C Riñón, M S García Muñoz, M L Ruiz Caravaca, J L Miguel.   

Abstract

The presence of genetic prothrombotic factors (factor V Leiden and the prothrombin II20210 mutation) was investigated in 38 patients with glomerulonephritis with or without a history of thrombotic events and/or nephrotic syndrome. We found an increased prevalence (36%) of heterozygous factor V Leiden in those patients with a history of thrombotic events. This is ten times the prevalence in the normal Spanish population. Carrier status for this mutation may be a determining factor in the development of thrombotic events along with the acquired disorders of coagulation to which these patients are prone. We found only one patient who was a carrier of the G-A II20210 mutation of the prothrombin gene; this patient had no history of venous thrombosis or embolism. Our findings suggest the need to measure activated protein C resistance and to look for the most frequent genotype causing it, Factor V Leiden, in patients with glomerulonephritis to identify those at risk who may benefit from prophylaxis against thrombosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853194

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  2 in total

1.  Postoperative Intracardiac Thrombus in a Child with Nephrotic Syndrome.

Authors:  Khadijah Maghrabi; Ruba Aldhaheri; Nora Aljunaid; Amal Saeed Alzahrani; Hanan Mohammad Alsayyad; Nada Kalakattawi; Osama Safdar
Journal:  Int Med Case Rep J       Date:  2022-03-10

2.  Thromboembolic complications in childhood nephrotic syndrome: a clinical profile.

Authors:  Deepti Suri; Jasmina Ahluwalia; Akshay K Saxena; Kushaljit S Sodhi; Paramjeet Singh; Bhagwant R Mittal; Reena Das; Amit Rawat; Surjit Singh
Journal:  Clin Exp Nephrol       Date:  2013-12-18       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.